BE VONVENDI® VIBRANT

EMBRACE LIFE IN FULL COLOR

View latest data in pediatrics

View latest prophylaxis data in adults

style
Alternate, Mobile Reverse, Bare, Box Shadow, No Bottom Margin, Gradient Title

VONVENDI is indicated for

Prophylaxis1

Routine prophylaxis to reduce the frequency of bleeding episodes in adult patients with VWD

View prophylaxis data

On-demand1

On-demand treatment and control of bleeding episodes in adult and pediatric patients with VWD

View on-demand data

Surgery1

Perioperative management of bleeding in adult and pediatric patients with VWD

View surgery data

style
center

Now approved for pediatric patients1-5

VONVENDI is the first and only recombinant therapy approved for on-demand and perioperative use in pediatric VWD patients. Learn more about the clinical trials that helped establish its efficacy and safety profile for pediatric patients. VONVENDI is not approved for prophylaxis in pediatric patients.

Explore pediatric data

VONVENDI is unique

Contains the full range of VWF multimers1

Because of its recombinant manufacturing process, VONVENDI is the only VWF concentrate not exposed to ADAMTS13, allowing its ultra-large multimers to remain intact.


The impact of multimeric composition and mechanism of action on clinical efficacy is unknown.

Uniquely long half-life1

VONVENDI has a uniquely long half-life (22.6 hours for adults and 14 hours for pediatric patients), and promoted an increase in VWF activity levels (VWF:RCo).

Enables a sustained rise in FVIII levels1

In adults, endogenous FVIII:C levels rose at a mean rate of 7.7% per hour (range 1.0%-17.2%) for the first 6 hours6*

*PK analyses in adults were performed post hoc from pooled data across on-demand and surgery trials (N=40).

style
Center

VONVENDI is the first and only recombinant VWF treatment option for VWD.1-4

Recombinant products are manufactured without blood or human plasma, virtually eliminating the risk of blood-borne pathogen transmission.7-8

style
Center, Content Width SM
Discover how VONVENDI is made to be different

Learn more

style
Center, Light Blue, Contained SM
Stand­alone VONVENDI® prescription vials.

Let your patients try it for free

Takeda’s FREEDOM OF CHOICE™ Trial Program provides trial doses of VONVENDI at no cost to eligible patients with von Willebrand disease.1 This program is available to new VONVENDI patients only and must be for an approved use.

Learn about the program

style
Content Width SM
REFERENCES
  1. VONVENDI [von Willebrand factor (Recombinant)] Prescribing Information.
  2. ALPHANATE [antihemophilic factor/von Willebrand factor complex (human)] Prescribing Information.
  3. HUMATE-P [Antihemophilic Factor/von Willebrand Factor Complex (Human)] Prescribing Information.
  4. WILATE [von Willebrand Factor/Coagulation Factor VIII Complex (Human)] Prescribing Information.
  5. Takeda Pharmaceutical Company Limited. FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD). Business Wire. Published January 31, 2022. Accessed September 12, 2025. https://www.businesswire.com/news/home/20220131005214/en
  6. Data on file, Takeda, Inc.
  7. Turecek PL, Mitterer A, Matthiessen HP. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hämostaseologie. 2009;29(suppl 1):S32-S38.
  8. Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
style
References, Content Width SM